Long-term protection of HPV test in women at risk of cervical cancer
To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cumulative adherence to perform a next test in a cohort of women aged 40+ years with no cervical screening cytology within a window of 5 years (underscreened women), after baseline cervical cytology a...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-08, Vol.15 (8), p.e0237988-e0237988 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0237988 |
|---|---|
| container_issue | 8 |
| container_start_page | e0237988 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Ibanez, Raquel Roura, Esther Monfil, Laura Rodriguez, Luís Alejandro Sarda, Montserrat Crespo, Nayade Pascual, Amparo Marti, Clara Fibla, Montserrat Gutierrez, Cristina Lloveras, Belen Oliveras, Gloria Torrent, Anna Catala, Isabel Bosch, Francesc Xavier Bruni, Laia de Sanjose, Silvia |
| description | To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cumulative adherence to perform a next test in a cohort of women aged 40+ years with no cervical screening cytology within a window of 5 years (underscreened women), after baseline cervical cytology and HPV tests. In Catalonia, Spain, co-testing with cytology and HPV test has been recommended in the Public Health system since 2006 for underscreened women. In 2007, 1,594 women with underscreened criteria were identified and followed through medical records form Pathological Department. 9-year cumulative incidence of histologically confirmed CIN2+ and cumulative adherence to perform a next test were estimated using Kaplan-Meier statistics. Follow-up was available for 1,009 women (63.3%) resulting in 23 women with. CIN2+ (2.3%). Of them, 4 women (17%) had both tests negative at baseline (3CIN2 and 1CIN3) with cumulative incidence of CIN2+ of 0.4% (95% CI: 0.1-1.4) at 5-years and 1.3% (95% CI: 0.4-3.7) at 9-years. During the first year, the prevalence among women with both tests positive was 27.0% (95% CI: 13.0-50.6) for CIN2+. Lost to follow-up was higher among women with both tests negative compared to those with both positive tests (38.7% vs 4.2%, p-value |
| doi_str_mv | 10.1371/journal.pone.0237988 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2437832405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A633690466</galeid><doaj_id>oai_doaj_org_article_b60c425ac7d54ebf9d4b4374238b08c7</doaj_id><sourcerecordid>A633690466</sourcerecordid><originalsourceid>FETCH-LOGICAL-c669t-8d3ecb5215222e4abfa50e1f9cb1685811fbfafd35534c79cce877647a262e713</originalsourceid><addsrcrecordid>eNqNkl2L1DAUhoso7jr6DwQLgujFjM1Hk_RGWNaPHRhY8WNvQ5qezmRskzFJV_33pjtVtrIXkouEc57znpzDm2VPUbFChKPXezd4q7rVwVlYFZjwSoh72SmqCF4yXJD7t94n2aMQ9kVREsHYw-yEYFESjNhp9nbj7HYZwff5wbsIOhpnc9fmFx-v8ggh5sbmP1wPNlcx9yZ8G5Ma_LXRqsu1sun9OHvQqi7Ak-leZF_fv_tyfrHcXH5Yn59tlpqxKi5FQ0DXJUYlxhioqltVFoDaSteIiVIg1KZQ25CyJFTzSmsQnDPKFWYYOCKL7NlR99C5IKcFBIkp4YJgmsZbZOsj0Ti1lwdveuV_SaeMvAk4v5XKR6M7kDUrNMWl0rwpKdRt1dA6CVFMRF0IzZPWm6nbUPfQaLDRq24mOs9Ys5Nbdy05LRGjIgm8nAS8-z6kXcreBA1dpyy44ebfgvE0K0vo83_Qu6ebqK1KAxjbutRXj6LyjBHCqoKyUWt1B5VOA73RyS2tSfFZwatZQWIi_IxbNYQg158__T97eTVnX9xid6C6uAuuG0aLhTlIj6D2LgQP7d8lo0KOZv-zDTmaXU5mJ78BtovuIw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437832405</pqid></control><display><type>article</type><title>Long-term protection of HPV test in women at risk of cervical cancer</title><source>PubMed Central Free</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Ibanez, Raquel ; Roura, Esther ; Monfil, Laura ; Rodriguez, Luís Alejandro ; Sarda, Montserrat ; Crespo, Nayade ; Pascual, Amparo ; Marti, Clara ; Fibla, Montserrat ; Gutierrez, Cristina ; Lloveras, Belen ; Oliveras, Gloria ; Torrent, Anna ; Catala, Isabel ; Bosch, Francesc Xavier ; Bruni, Laia ; de Sanjose, Silvia</creator><contributor>Tornesello, Maria Lina</contributor><creatorcontrib>Ibanez, Raquel ; Roura, Esther ; Monfil, Laura ; Rodriguez, Luís Alejandro ; Sarda, Montserrat ; Crespo, Nayade ; Pascual, Amparo ; Marti, Clara ; Fibla, Montserrat ; Gutierrez, Cristina ; Lloveras, Belen ; Oliveras, Gloria ; Torrent, Anna ; Catala, Isabel ; Bosch, Francesc Xavier ; Bruni, Laia ; de Sanjose, Silvia ; Tornesello, Maria Lina</creatorcontrib><description>To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cumulative adherence to perform a next test in a cohort of women aged 40+ years with no cervical screening cytology within a window of 5 years (underscreened women), after baseline cervical cytology and HPV tests. In Catalonia, Spain, co-testing with cytology and HPV test has been recommended in the Public Health system since 2006 for underscreened women. In 2007, 1,594 women with underscreened criteria were identified and followed through medical records form Pathological Department. 9-year cumulative incidence of histologically confirmed CIN2+ and cumulative adherence to perform a next test were estimated using Kaplan-Meier statistics. Follow-up was available for 1,009 women (63.3%) resulting in 23 women with. CIN2+ (2.3%). Of them, 4 women (17%) had both tests negative at baseline (3CIN2 and 1CIN3) with cumulative incidence of CIN2+ of 0.4% (95% CI: 0.1-1.4) at 5-years and 1.3% (95% CI: 0.4-3.7) at 9-years. During the first year, the prevalence among women with both tests positive was 27.0% (95% CI: 13.0-50.6) for CIN2+. Lost to follow-up was higher among women with both tests negative compared to those with both positive tests (38.7% vs 4.2%, p-value <0.001). 40.5% of the women HPV-/cyto- had a re-screening test during the 4 years following the baseline, increasing until 53.5% during the 6 years of follow-up. HPV detection shows a high longitudinal predictive value at 9-year to identify women at risk to develop CIN2+. The data validate a safe extension of the 3-year screening intervals (current screening interval) to 5-year intervals in underscreened women that had negative HPV result at baseline. It is necessary to establish mechanisms to ensure screening participation and adequate follow-up for these women.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0237988</identifier><identifier>PMID: 32853216</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Biology and Life Sciences ; Cancer screening ; Cellular biology ; Cervical cancer ; Cervix ; Clinical trials ; Cytology ; Diagnosis ; Epidemiology ; Evaluation ; Health risks ; Human papillomavirus ; Immunologic tests ; Infections ; Intervals ; Laboratories ; Medical diagnosis ; Medical records ; Medical screening ; Medicine and Health Sciences ; Methods ; Mortality ; Oncology ; Papillomavirus infections ; Pathology ; Patient outcomes ; Public health ; Reproductive health ; Risk factors ; Statistical tests ; Women's health ; Womens health</subject><ispartof>PloS one, 2020-08, Vol.15 (8), p.e0237988-e0237988</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Ibáñez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Ibáñez et al 2020 Ibáñez et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c669t-8d3ecb5215222e4abfa50e1f9cb1685811fbfafd35534c79cce877647a262e713</citedby><cites>FETCH-LOGICAL-c669t-8d3ecb5215222e4abfa50e1f9cb1685811fbfafd35534c79cce877647a262e713</cites><orcidid>0000-0003-3324-8312 ; 0000-0003-4620-9291</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451648/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451648/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids></links><search><contributor>Tornesello, Maria Lina</contributor><creatorcontrib>Ibanez, Raquel</creatorcontrib><creatorcontrib>Roura, Esther</creatorcontrib><creatorcontrib>Monfil, Laura</creatorcontrib><creatorcontrib>Rodriguez, Luís Alejandro</creatorcontrib><creatorcontrib>Sarda, Montserrat</creatorcontrib><creatorcontrib>Crespo, Nayade</creatorcontrib><creatorcontrib>Pascual, Amparo</creatorcontrib><creatorcontrib>Marti, Clara</creatorcontrib><creatorcontrib>Fibla, Montserrat</creatorcontrib><creatorcontrib>Gutierrez, Cristina</creatorcontrib><creatorcontrib>Lloveras, Belen</creatorcontrib><creatorcontrib>Oliveras, Gloria</creatorcontrib><creatorcontrib>Torrent, Anna</creatorcontrib><creatorcontrib>Catala, Isabel</creatorcontrib><creatorcontrib>Bosch, Francesc Xavier</creatorcontrib><creatorcontrib>Bruni, Laia</creatorcontrib><creatorcontrib>de Sanjose, Silvia</creatorcontrib><title>Long-term protection of HPV test in women at risk of cervical cancer</title><title>PloS one</title><description>To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cumulative adherence to perform a next test in a cohort of women aged 40+ years with no cervical screening cytology within a window of 5 years (underscreened women), after baseline cervical cytology and HPV tests. In Catalonia, Spain, co-testing with cytology and HPV test has been recommended in the Public Health system since 2006 for underscreened women. In 2007, 1,594 women with underscreened criteria were identified and followed through medical records form Pathological Department. 9-year cumulative incidence of histologically confirmed CIN2+ and cumulative adherence to perform a next test were estimated using Kaplan-Meier statistics. Follow-up was available for 1,009 women (63.3%) resulting in 23 women with. CIN2+ (2.3%). Of them, 4 women (17%) had both tests negative at baseline (3CIN2 and 1CIN3) with cumulative incidence of CIN2+ of 0.4% (95% CI: 0.1-1.4) at 5-years and 1.3% (95% CI: 0.4-3.7) at 9-years. During the first year, the prevalence among women with both tests positive was 27.0% (95% CI: 13.0-50.6) for CIN2+. Lost to follow-up was higher among women with both tests negative compared to those with both positive tests (38.7% vs 4.2%, p-value <0.001). 40.5% of the women HPV-/cyto- had a re-screening test during the 4 years following the baseline, increasing until 53.5% during the 6 years of follow-up. HPV detection shows a high longitudinal predictive value at 9-year to identify women at risk to develop CIN2+. The data validate a safe extension of the 3-year screening intervals (current screening interval) to 5-year intervals in underscreened women that had negative HPV result at baseline. It is necessary to establish mechanisms to ensure screening participation and adequate follow-up for these women.</description><subject>Biology and Life Sciences</subject><subject>Cancer screening</subject><subject>Cellular biology</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Clinical trials</subject><subject>Cytology</subject><subject>Diagnosis</subject><subject>Epidemiology</subject><subject>Evaluation</subject><subject>Health risks</subject><subject>Human papillomavirus</subject><subject>Immunologic tests</subject><subject>Infections</subject><subject>Intervals</subject><subject>Laboratories</subject><subject>Medical diagnosis</subject><subject>Medical records</subject><subject>Medical screening</subject><subject>Medicine and Health Sciences</subject><subject>Methods</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Papillomavirus infections</subject><subject>Pathology</subject><subject>Patient outcomes</subject><subject>Public health</subject><subject>Reproductive health</subject><subject>Risk factors</subject><subject>Statistical tests</subject><subject>Women's health</subject><subject>Womens health</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl2L1DAUhoso7jr6DwQLgujFjM1Hk_RGWNaPHRhY8WNvQ5qezmRskzFJV_33pjtVtrIXkouEc57znpzDm2VPUbFChKPXezd4q7rVwVlYFZjwSoh72SmqCF4yXJD7t94n2aMQ9kVREsHYw-yEYFESjNhp9nbj7HYZwff5wbsIOhpnc9fmFx-v8ggh5sbmP1wPNlcx9yZ8G5Ma_LXRqsu1sun9OHvQqi7Ak-leZF_fv_tyfrHcXH5Yn59tlpqxKi5FQ0DXJUYlxhioqltVFoDaSteIiVIg1KZQ25CyJFTzSmsQnDPKFWYYOCKL7NlR99C5IKcFBIkp4YJgmsZbZOsj0Ti1lwdveuV_SaeMvAk4v5XKR6M7kDUrNMWl0rwpKdRt1dA6CVFMRF0IzZPWm6nbUPfQaLDRq24mOs9Ys5Nbdy05LRGjIgm8nAS8-z6kXcreBA1dpyy44ebfgvE0K0vo83_Qu6ebqK1KAxjbutRXj6LyjBHCqoKyUWt1B5VOA73RyS2tSfFZwatZQWIi_IxbNYQg158__T97eTVnX9xid6C6uAuuG0aLhTlIj6D2LgQP7d8lo0KOZv-zDTmaXU5mJ78BtovuIw</recordid><startdate>20200827</startdate><enddate>20200827</enddate><creator>Ibanez, Raquel</creator><creator>Roura, Esther</creator><creator>Monfil, Laura</creator><creator>Rodriguez, Luís Alejandro</creator><creator>Sarda, Montserrat</creator><creator>Crespo, Nayade</creator><creator>Pascual, Amparo</creator><creator>Marti, Clara</creator><creator>Fibla, Montserrat</creator><creator>Gutierrez, Cristina</creator><creator>Lloveras, Belen</creator><creator>Oliveras, Gloria</creator><creator>Torrent, Anna</creator><creator>Catala, Isabel</creator><creator>Bosch, Francesc Xavier</creator><creator>Bruni, Laia</creator><creator>de Sanjose, Silvia</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3324-8312</orcidid><orcidid>https://orcid.org/0000-0003-4620-9291</orcidid></search><sort><creationdate>20200827</creationdate><title>Long-term protection of HPV test in women at risk of cervical cancer</title><author>Ibanez, Raquel ; Roura, Esther ; Monfil, Laura ; Rodriguez, Luís Alejandro ; Sarda, Montserrat ; Crespo, Nayade ; Pascual, Amparo ; Marti, Clara ; Fibla, Montserrat ; Gutierrez, Cristina ; Lloveras, Belen ; Oliveras, Gloria ; Torrent, Anna ; Catala, Isabel ; Bosch, Francesc Xavier ; Bruni, Laia ; de Sanjose, Silvia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c669t-8d3ecb5215222e4abfa50e1f9cb1685811fbfafd35534c79cce877647a262e713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biology and Life Sciences</topic><topic>Cancer screening</topic><topic>Cellular biology</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Clinical trials</topic><topic>Cytology</topic><topic>Diagnosis</topic><topic>Epidemiology</topic><topic>Evaluation</topic><topic>Health risks</topic><topic>Human papillomavirus</topic><topic>Immunologic tests</topic><topic>Infections</topic><topic>Intervals</topic><topic>Laboratories</topic><topic>Medical diagnosis</topic><topic>Medical records</topic><topic>Medical screening</topic><topic>Medicine and Health Sciences</topic><topic>Methods</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Papillomavirus infections</topic><topic>Pathology</topic><topic>Patient outcomes</topic><topic>Public health</topic><topic>Reproductive health</topic><topic>Risk factors</topic><topic>Statistical tests</topic><topic>Women's health</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ibanez, Raquel</creatorcontrib><creatorcontrib>Roura, Esther</creatorcontrib><creatorcontrib>Monfil, Laura</creatorcontrib><creatorcontrib>Rodriguez, Luís Alejandro</creatorcontrib><creatorcontrib>Sarda, Montserrat</creatorcontrib><creatorcontrib>Crespo, Nayade</creatorcontrib><creatorcontrib>Pascual, Amparo</creatorcontrib><creatorcontrib>Marti, Clara</creatorcontrib><creatorcontrib>Fibla, Montserrat</creatorcontrib><creatorcontrib>Gutierrez, Cristina</creatorcontrib><creatorcontrib>Lloveras, Belen</creatorcontrib><creatorcontrib>Oliveras, Gloria</creatorcontrib><creatorcontrib>Torrent, Anna</creatorcontrib><creatorcontrib>Catala, Isabel</creatorcontrib><creatorcontrib>Bosch, Francesc Xavier</creatorcontrib><creatorcontrib>Bruni, Laia</creatorcontrib><creatorcontrib>de Sanjose, Silvia</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ibanez, Raquel</au><au>Roura, Esther</au><au>Monfil, Laura</au><au>Rodriguez, Luís Alejandro</au><au>Sarda, Montserrat</au><au>Crespo, Nayade</au><au>Pascual, Amparo</au><au>Marti, Clara</au><au>Fibla, Montserrat</au><au>Gutierrez, Cristina</au><au>Lloveras, Belen</au><au>Oliveras, Gloria</au><au>Torrent, Anna</au><au>Catala, Isabel</au><au>Bosch, Francesc Xavier</au><au>Bruni, Laia</au><au>de Sanjose, Silvia</au><au>Tornesello, Maria Lina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term protection of HPV test in women at risk of cervical cancer</atitle><jtitle>PloS one</jtitle><date>2020-08-27</date><risdate>2020</risdate><volume>15</volume><issue>8</issue><spage>e0237988</spage><epage>e0237988</epage><pages>e0237988-e0237988</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cumulative adherence to perform a next test in a cohort of women aged 40+ years with no cervical screening cytology within a window of 5 years (underscreened women), after baseline cervical cytology and HPV tests. In Catalonia, Spain, co-testing with cytology and HPV test has been recommended in the Public Health system since 2006 for underscreened women. In 2007, 1,594 women with underscreened criteria were identified and followed through medical records form Pathological Department. 9-year cumulative incidence of histologically confirmed CIN2+ and cumulative adherence to perform a next test were estimated using Kaplan-Meier statistics. Follow-up was available for 1,009 women (63.3%) resulting in 23 women with. CIN2+ (2.3%). Of them, 4 women (17%) had both tests negative at baseline (3CIN2 and 1CIN3) with cumulative incidence of CIN2+ of 0.4% (95% CI: 0.1-1.4) at 5-years and 1.3% (95% CI: 0.4-3.7) at 9-years. During the first year, the prevalence among women with both tests positive was 27.0% (95% CI: 13.0-50.6) for CIN2+. Lost to follow-up was higher among women with both tests negative compared to those with both positive tests (38.7% vs 4.2%, p-value <0.001). 40.5% of the women HPV-/cyto- had a re-screening test during the 4 years following the baseline, increasing until 53.5% during the 6 years of follow-up. HPV detection shows a high longitudinal predictive value at 9-year to identify women at risk to develop CIN2+. The data validate a safe extension of the 3-year screening intervals (current screening interval) to 5-year intervals in underscreened women that had negative HPV result at baseline. It is necessary to establish mechanisms to ensure screening participation and adequate follow-up for these women.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>32853216</pmid><doi>10.1371/journal.pone.0237988</doi><tpages>e0237988</tpages><orcidid>https://orcid.org/0000-0003-3324-8312</orcidid><orcidid>https://orcid.org/0000-0003-4620-9291</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-08, Vol.15 (8), p.e0237988-e0237988 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2437832405 |
| source | PubMed Central Free; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
| subjects | Biology and Life Sciences Cancer screening Cellular biology Cervical cancer Cervix Clinical trials Cytology Diagnosis Epidemiology Evaluation Health risks Human papillomavirus Immunologic tests Infections Intervals Laboratories Medical diagnosis Medical records Medical screening Medicine and Health Sciences Methods Mortality Oncology Papillomavirus infections Pathology Patient outcomes Public health Reproductive health Risk factors Statistical tests Women's health Womens health |
| title | Long-term protection of HPV test in women at risk of cervical cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T01%3A05%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20protection%20of%20HPV%20test%20in%20women%20at%20risk%20of%20cervical%20cancer&rft.jtitle=PloS%20one&rft.au=Ibanez,%20Raquel&rft.date=2020-08-27&rft.volume=15&rft.issue=8&rft.spage=e0237988&rft.epage=e0237988&rft.pages=e0237988-e0237988&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0237988&rft_dat=%3Cgale_plos_%3EA633690466%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437832405&rft_id=info:pmid/32853216&rft_galeid=A633690466&rft_doaj_id=oai_doaj_org_article_b60c425ac7d54ebf9d4b4374238b08c7&rfr_iscdi=true |